rs2066865 — FGG 10034C>T

The Fibrinogen Gamma Isoform Switch — How rs2066865 Tilts the Clotting Balance

Fibrinogen is the blood's primary scaffolding protein — the raw material that thrombin converts into fibrin, the structural backbone of every blood clot. But fibrinogen is not a single molecule. The liver produces two principal isoforms that differ at their gamma chain tip: fibrinogen gamma-A¹¹ fibrinogen gamma-A
The predominant isoform (~85-90% of total fibrinogen) with standard interactions with thrombin, platelets, and Factor XIII and fibrinogen gamma-prime²² fibrinogen gamma-prime
A minority isoform (~10-15% of total) with an extended gamma chain that uniquely binds thrombin, Factor XIII, and has distinct platelet interactions. The rs2066865 variant determines how much gamma-prime your liver makes relative to gamma-A — and that ratio turns out to matter for your thrombosis risk.

The Mechanism

The FGG gene on chromosome 4 encodes the fibrinogen gamma chain. Two alternative polyadenylation sites in its 3' downstream region³³ 3' downstream region
The non-coding region after the gene's stop codon that controls mRNA processing and determines which protein isoform is produced create two mRNA transcripts: a shorter one producing the standard gamma-A chain and a longer one producing the extended gamma-prime chain. The rs2066865 variant (10034C>T on the coding strand; G>A on the plus strand) sits in this alternative splicing control region and shifts the balance toward the shorter transcript — meaning carriers of the A allele produce proportionally less fibrinogen gamma-prime and more gamma-A.

Fibrinogen gamma-prime has several unique properties that modulate clot risk. It binds thrombin with high affinity through exosite II, effectively sequestering thrombin and limiting its availability for further coagulation. It also alters clot architecture⁴⁴ clot architecture
Fibrinogen gamma-prime produces clots with a looser, more porous structure that is more easily dissolved by fibrinolysis — the body's clot-clearing system. When gamma-prime levels fall (as in A-allele carriers), clots form more readily and are more resistant to fibrinolysis — a procoagulant shift by two independent mechanisms simultaneously.

The Evidence

The original landmark study by Uitte de Willige et al.⁵⁵ Uitte de Willige et al.
Published in Blood 2005, the first paper to identify rs2066865 as an independent DVT risk factor identified this variant as an independent deep venous thrombosis risk factor through the gamma-prime fibrinogen mechanism. The largest genetic confirmation came from a UK Biobank and Veterans Affairs genome-wide study by Klarin et al.⁶⁶ UK Biobank and Veterans Affairs genome-wide study by Klarin et al.
816,694 participants; p-value 10⁻⁸⁸ for VTE association; OR 1.22 per A allele — one of the strongest genetic signals in the VTE literature with over 800,000 participants, establishing an odds ratio of approximately 1.22 per A allele at genome-wide significance (p = 10⁻⁸⁸).

In a prospective population-based study from Norway⁷⁷ prospective population-based study from Norway
640 VTE cases among 3,734 age-weighted participants in the Tromsø cohort, homozygous AA carriers showed a hazard ratio of 1.7 (95% CI 1.2–2.3) for VTE. When active cancer was present, the risk compounded further to HR 2.0 — synergy between genetic and acquired thrombotic risk.

A large Czech study of 2,630 VTE patients versus 2,637 controls⁸⁸ 2,630 VTE patients versus 2,637 controls
Kvasnicka et al. 2025, Clinical and Applied Thrombosis/Hemostasis confirmed a dose-response relationship: heterozygous GA carriers had 1.37-fold increased VTE risk and homozygous AA carriers had 1.77-fold increased risk. A separate microvascular surgery cohort found microvascular thrombosis rates of 7.6% (GG), 22.7% (GA), and 33% (AA)⁹⁹ microvascular thrombosis rates of 7.6% (GG), 22.7% (GA), and 33% (AA)
Drizlionoka et al. 2019; 104 patients undergoing microvascular flap surgery, with plasma fibrinogen concentrations also rising with each A allele.

The association extends beyond venous thrombosis. In Han Chinese participants¹⁰¹⁰ Han Chinese participants
Discovery and replication cohorts totaling 1,268 PE cases and 17,663 controls, rs2066865 reached genome-wide significance for pulmonary embolism (p = 3.81 × 10⁻¹⁴, OR 1.37). In systemic lupus erythematosus patients, the variant showed OR 1.91 for venous thrombosis in white participants and OR 2.19 for arterial thrombosis in Hispanic Americans — suggesting that the procoagulant phenotype interacts with the inflammatory milieu of autoimmune disease.

Practical Implications

The per-allele OR of ~1.22 translates to a moderate absolute risk increase. Unlike the rare, high-penetrance thrombophilias (Factor V Leiden homozygosity, antithrombin deficiency), rs2066865 is common enough — about 7% of people carry two A alleles — that it contributes meaningfully to population-attributable VTE burden. The effect is additive: each additional A allele incrementally shifts the gamma/gamma-prime ratio and modestly elevates risk.

For carriers, awareness is most actionable before high-risk periods: surgery, prolonged immobilization, long-haul travel, hormonal changes (pregnancy, oral contraceptive initiation), and during cancer treatment. The variant also modifies fibrinogen levels measurably — AA homozygotes in the Drizlionoka cohort had nearly double the plasma fibrinogen of GG homozygotes — which is itself an established cardiovascular risk factor.

Interactions

The most clinically important interactions are with other inherited thrombophilias. Carriers of both rs2066865 A allele(s) and Factor V Leiden (rs6025)¹¹¹¹ Factor V Leiden (rs6025)
F5 R506Q, the most common inherited thrombophilia at 5% carrier frequency in Europeans; creates resistance to activated protein C, a natural anticoagulant or prothrombin G20210A (rs1799963)¹²¹² prothrombin G20210A (rs1799963)
F2 3'UTR variant that elevates prothrombin production by 30%; the second most common inherited thrombophilia face a compounded risk from independent pro-coagulant mechanisms acting simultaneously. Similarly, Factor XI rs2289252¹³¹³ Factor XI rs2289252
F11 intronic variant associated with elevated Factor XI levels and modestly elevated VTE risk is included in clinical thrombophilia panels alongside rs2066865. Acquired thrombophilic states — cancer, antiphospholipid syndrome, pregnancy — add independently to the genetic baseline.